GSK’s Witty Heralds Success Of New Sales Model, Reassures Over Advair
Executive Summary
GlaxoSmithKline isn't losing too much sleep over imminent generic competition in the US for Advair and CEO Andrew Witty explains why he expects biologics-like economic dynamics for the product. The CEO also outlined the measurable gains of GSK's new model for engaging with healthcare professionals at a media interaction in India.
You may also be interested in...
KOL Webinars Get Maximum Bang For Pharma's Digital Buck?
Digital channels are expected to consume more of pharma's marketing dollars – China and the US already trump the rest of the world in terms of non-personal digital spends, while pharma marketers see webinars with key opinion leaders (KOLs) as the channel that generates the highest return on investment (ROI).
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.